“GSK Awarded Supply of Meningococcal Vaccine in Balearic Islands, Saves Government More Than 14%”

GSK gains ground in the Balearic Islands. The Balearic Government has awarded the supply of vaccines against group B meningococcus to Glaxosmithkline (GSK) for a value of 2.7 million euros, according to the adjudication file presented by the Conselleria de Salut i Consum of the region.

The agreement has an execution period that ends at the end of 2024, but it can be extended for another two years. The Balearic Government published the tender with a value of 68 euros per unit, budgeting a total amount of 3.1 million euros.

Finally, it has been awarded to the GSK company, with its vaccine called Bexsero, which offered a unit value of 58 euros each dosewhich represents a saving of 14.71% to the regional government.

GSK will provide more than 46,000 doses of vaccines to the Balearic executive

The contract dictates the supply of 46,000 doses of vaccines to combat the bacteria that can cause meningitiswith 18,000 doses being supplied in 2023, with an amount of more than one million euros, while the remaining 28,000 doses would be provided over the next year, with a disbursement of 1.6 million more euros.

In the bidding process, Pfizer has joined the British company, but the pharmaceutical company was rejected for “not complying with the required technical prescriptions, since its administration is not indicated for the population for which it is intended, according to the calendar of vaccination (children at two, four and twelve months of age)”.

Unlike Pfizer’s vaccine, called Trumenba, Bexsero doses can be given at all ages. Vaccines against group B meningococcus are used to combat the bacteria that cause meningitis and sepsis, which is a blood infection, and which can cause serious sequelae or even lead to death in one in ten cases.

The pharmaceutical company GSK tripled its profits in 2022, reaching 17,728 million euros

GSK is a British pharmaceutical company that arises from the merger of Glaxo Wellcome and SmithKline Beecham. The company closed 2021 with a profit of 17,728 million euros in 2022, triple that of the previous year.

The group argued the increase in profit from the spin-off of the company in the middle of 2022 with the creation of Haleon, which is listed on the London Stock Exchange, and is focused on consumer pharmaceuticals.. In that year, the company reached a turnover of 33,324 million euros in 2022, which represents an increase of 13% compared to the previous year.

Among the latest movements of the pharmaceutical company in Spain, the award of 11,300 doses of zoster vaccine in Aragon for a value of 1.7 million euros stands out. This pathology involves the eruption of a rash or blisters on the skin and is caused by the varicella-zoster virus, the same one that causes chickenpox and remains in the body once the disease is over.